Pharma Exclusives Pressreleases
Eleva and 3PBIOVIAN Sign Strategic GMP Manufacturing and Technology Alliance to Boost Capacity for Eleva’s Platform and Pipeline
Tuesday, February 04, 2025Eleva a pioneer in unlocking difficulttoproduce biologics based on a breakthrough manufacturing platform and PBIOVIAN a leading contract development and manufacturing organization CDMO announced today a strategic alliance
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Tuesday, February 04, 2025ProBioGen has launched its new redesigned website to provide biotech and biopharma professionals with clear access to its expanded services and proprietary technologies The platform delivers an intuitive userfocused experience and faster access to es...
Thermo Fisher Scientific Accelerates 100 Percent Renewable Electricity Goal for European Operations with New Solar Power Agreement with X-ELIO
Tuesday, February 04, 2025Thermo Fisher Scientific Incthe world leader in serving science today announced a year virtual power purchasing agreement VPPA with international renewable energy developer XELIO designed to increase access to renewable electricity across the pharmac...
Bayer files for approval of finerenone in heart failure in the EU
Monday, February 03, 2025Bayer today announced the submission of a marketing authorization application to the European Medicines Agency EMA seeking approval in the EU for the use of finerenone in adult patients with HF with a left ventricular ejection fraction LVEF of ie mi...
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Friday, January 31, 2025Eisai Co Ltdand Biogen Inc Nasdaq BIIB Corporate headquarters Cambridge Massachusetts CEO Christopher A Viehbacher Biogen announced today an update on the ongoing regulatory review of the Marketing Authorization Application
Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer
Tuesday, January 28, 2025Rocheannounced today positive topline results from the overall survival OS analysis of the phase III INAVO study investigating ItovebiTM inavolisib in combination with palbociclib Ibrance and fulvestrant for people with PIKCAmutated hormone receptor...
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)
Monday, January 27, 2025Roche announced today positive topline results from year two of the EMBARK trial a global randomised doubleblind phase III study of Elevidys delandistrogene moxeparvovec the first approved gene therapy for the treatment of individuals with Duchenne m...
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
Monday, January 27, 2025Innate Pharma SA today announced the first patient was dosed in its Phase study NCT investigating the safety and tolerability of IPH an innovative AntibodyDrug Conjugate ADC in patients with advanced solid tumors known to express Nectin
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Friday, January 24, 2025Biogen Incannounced that the US Food and Drug Administration FDA has accepted the companys supplemental New Drug Application sNDA and the European Medicines Agency EMA has validated the application for a higher dose regimen of nusinersen for spinal m...
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Friday, January 24, 2025Novo Nordisk today announced topline results from a phase ba clinical trial with amycretin a unimolecular GLP and amylin receptor agonist intended for once weekly subcutaneous administration
